Trial Profile
A Multicenter, Randomized, Double-blind, Placebo Controlled Study to Explore the Effective Doses and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets in Patients With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2020
Price :
$35
*
At a glance
- Drugs Hypidone Hydrochloride (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Shanghai Synergy Pharmaceutical Sciences; Zhejiang Huahai Pharmaceutical
- 25 Dec 2019 Status changed from not yet recruiting to completed.
- 20 Nov 2018 New trial record